This website has been developed by Besins Healthcare (UK) Ltd. This website has separate sections for healthcare professionals and patients who have been prescribed Testogel® 16.2 mg/g gel, within the UK.

Besins Healthcare is a pharmaceutical company specialising in the development of innovative drugs for the well-being of men and women throughout their life.

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Testosterone therapy
(TTh)

Overview

Testosterone deficiency (TD) is treatable.1 

The aim of TTh is to restore testosterone levels to the normal physiological range and to improve symptoms of TD. Symptoms associated with TD such as reduced bone mineral density, or poor glycaemic control, may not be directly visible to the patient and may require additional monitoring to see improvements.

Several testosterone preparations are available as TTh for the treatment of TD

Transdermal Gels
Transdermal gels
Intramuscular Injections
Intramuscular
injections
Oral Tablets
Oral tablets

References

  1. Hackett G, Kirby M, Edwards D, et al. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017;71(3–4:e12901).

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com